海森药业公告，公司董事代亚、副总经理张胜权、楼岩军及董秘胡康康已于2025年12月26日至12月31日 通过集中竞价合计减持10.29万股，占总股本0.0675%；其中代亚、张胜权、楼岩军、胡康康分别减持 24420股、25530股、25530股、24420股。财务总监潘爱娟已减持3000股，均价22.06元/股，并提前终止 剩余21420股减持计划。 ...

最新公告列表 近日，辰欣药业发布公告称，公司及控股子公司拟使用不超过29亿元的闲置自有资金进行委托理财及证 券投资，其中委托理财额度不超过23亿元，证券投资额度不超过6亿元，使用期限为董事会审议通过之 日起12个月，资金可滚动使用。投资范围包括银行理财产品、收益凭证、基金、国债、债券、ETF、股 票等。该事项已由公司第五届董事会第十一次会议审议通过，无需提交股东会审议。公司表示将加强风 险控制，防范市场、流动性等风险，并按规定披露相关进展。 截至2026年1月5日收盘，辰欣药业（603367）报收于18.21元，较前一交易日上涨5.14%，最新总市值为 82.45亿元。该股当日开盘17.42元，最高18.25元，最低17.42元，成交额达3.67亿元，换手率为4.52%。 《第五届董事会第十一次会议决议【签字盖章】》 《辰欣药业股份有限公司第五届董事会第十一次会议决议公告》 《辰欣药业股份有限公司关于公司及控股子公司使用闲置自有资金进行委托理财及证券投资的公 告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Viewpoint - Chenxin Pharmaceutical (603367) announced plans to utilize idle funds for entrusted wealth management and securities investment, with a total amount not exceeding 2.9 billion yuan, aiming to enhance the efficiency of fund usage and generate higher returns for shareholders [1] Group 1: Investment Plans - The company and its subsidiaries plan to use idle self-owned funds for entrusted wealth management and securities investment, with a total limit of 2.9 billion yuan, including up to 2.3 billion yuan for entrusted wealth management and up to 600 million yuan for securities investment [1] - The investment aims to improve the efficiency of idle funds while ensuring that the company's main business operations and daily capital needs are not affected [1] Group 2: Investment Types - Entrusted wealth management will primarily involve bank wealth management products, income certificates, and funds from financial institutions [1] - Securities investment will focus on government bonds or reverse repos, bonds, ETFs, stocks, and other investments permitted by laws and regulations [1]

Group 1 - The chemical pharmaceutical sector increased by 3.63% on January 5, with Frontier Biotech leading the gains [1] - The Shanghai Composite Index closed at 4023.42, up 1.38%, while the Shenzhen Component Index closed at 13828.63, up 2.24% [1] - Notable stock performances included Frontier Biotech with a closing price of 21.20, up 17.45%, and Beilu Pharmaceutical at 66.8, up 13.22% [1] Group 2 - The chemical pharmaceutical sector saw a net inflow of 716 million yuan from institutional investors, while retail investors contributed a net inflow of 131 million yuan [2] - Major stocks with significant net inflows included Heng Rui Pharmaceutical with 17.4 million yuan and ST Renfu with 9.15 million yuan [3] - Conversely, stocks like ST Jinfeng and Kangzhiyue experienced net outflows of 6.90 million yuan and 11.61 million yuan respectively [2][3]

（记者 王晓波） 每经头条（nbdtoutiao）——秒光！1499元飞天茅台上线即空，i茅台App冲上苹果购物榜第一，10万用 户已下单！经销商同价做回馈，1000箱很快卖完 每经AI快讯，海思科1月5日晚间发布公告称，公司第五届第三十三次董事会会议于2026年1月5日以通 讯表决方式召开。会议审议了《关于注销控股子公司暨关联交易的议案》等文件。 ...

（记者 王晓波） 每经AI快讯，普洛药业1月5日晚间发布公告称，截至2025年12月31日，公司通过回购专用证券账户以 集中竞价方式回购公司股份2037万股，占公司目前总股本的1.76%，最高成交价为16.85元/股，最低成 交价为15.71元/股，成交总金额约为3.32亿元。 每经头条（nbdtoutiao）——秒光！1499元飞天茅台上线即空，i茅台App冲上苹果购物榜第一，10万用 户已下单！经销商同价做回馈，1000箱很快卖完 ...

格隆汇1月5日丨富祥药业(300497.SZ)在投资者互动平台表示，公司具备生产99.99%和99.999%纯度VC 产品的能力，可根据客户订单要求进行生产。目前产能利用率良好。 ...

Core Viewpoint - Fujilay's stock price has shown a slight increase of 2.00% since the beginning of the year, with a current market capitalization of 3.039 billion yuan, indicating a stable performance in the pharmaceutical sector [1]. Group 1: Stock Performance - As of January 5, Fujilay's stock price reached 33.15 yuan per share, with a trading volume of 14.8913 million yuan and a turnover rate of 0.51% [1]. - The stock has experienced a 0.45% decline over the past five trading days, a 2.16% increase over the last 20 days, and a 1.37% decline over the past 60 days [1]. Group 2: Company Overview - Fujilay Pharmaceutical Co., Ltd. was established on November 27, 2000, and went public on March 29, 2022. The company is located in Changshu, Jiangsu Province [1]. - The main business activities include the research, production, and sales of active pharmaceutical ingredients (APIs) and health product raw materials [1]. - The revenue composition is as follows: 66.02% from lipoic acid products, 14.86% from carnosine products, 11.88% from etoricoxib, 5.95% from phosphatidylcholine products, and 1.29% from other supplements [1]. Group 3: Financial Performance - For the period from January to September 2025, Fujilay achieved an operating income of 323 million yuan, representing a year-on-year growth of 3.23%. The net profit attributable to the parent company was 73.3966 million yuan, showing a significant increase of 430.16% [1]. - Since its A-share listing, Fujilay has distributed a total of 153 million yuan in dividends, with 116 million yuan distributed over the past three years [2]. Group 4: Shareholder Information - As of December 19, 2025, the number of Fujilay's shareholders was 9,810, a slight decrease of 0.01% from the previous period, with an average of 9,079 circulating shares per person, which increased by 0.01% [1]. - As of September 30, 2025, the ninth largest circulating shareholder is Galaxy Kangle Stock A, holding 178,100 shares as a new shareholder [2].

数据显示，金元顺安基金旗下1只基金重仓亿帆医药。金元顺安宝石动力混合（620001）三季度持有股 数11.2万股，占基金净值比例为3.48%，位居第八大重仓股。根据测算，今日浮盈赚取约6.83万元。 金元顺安宝石动力混合（620001）成立日期2007年8月15日，最新规模4462.94万。今年以来收益 11.82%，同类排名5551/8155；近一年收益11.82%，同类排名5551/8155；成立以来收益45.7%。 金元顺安宝石动力混合（620001）基金经理为孔祥鹏、商昌层。 资料显示，亿帆医药股份有限公司位于浙江省杭州市临安区锦城街道琴山50号，成立日期2000年11月10 日，上市日期2004年7月13日，公司主营业务涉及生产和销售原料药、高分子材料。主营业务收入构成 为：医药自有产品(含进口)75.52%，维生素11.47%，医药其他产品9.52%，高分子材料3.00%，医药服务 0.49%。 从基金十大重仓股角度 1月5日，亿帆医药涨5.1%，截至发稿，报12.57元/股，成交2.04亿元，换手率1.96%，总市值152.90亿 元。 截至发稿，孔祥鹏累计任职时间8年194天，现任基金资产总规 ...

南方中证1000ETF（512100）基金经理为崔蕾。 数据显示，南方基金旗下1只基金位居海翔药业十大流通股东。南方中证1000ETF（512100）三季度减 持17.03万股，持有股数1035.83万股，占流通股的比例为0.64%。根据测算，今日浮盈赚取约372.9万 元。 南方中证1000ETF（512100）成立日期2016年9月29日，最新规模766.3亿。今年以来收益29.23%，同类 排名1828/4189；近一年收益29.23%，同类排名1828/4189；成立以来收益14.37%。 1月5日，海翔药业涨5.77%，截至发稿，报6.60元/股，成交1.05亿元，换手率1.01%，总市值106.84亿 元。 资料显示，浙江海翔药业股份有限公司位于浙江省台州市椒江区外沙支路100号，成立日期1998年5月7 日，上市日期2006年12月26日，公司主营业务涉及精细化学品(原料药中间体)和特色原料药(主要包括抗 生素类、抗病毒类、心血管类、驱虫类、降糖类等)的生产和销售;染料、染料中间体和颜料中间体的研 发、生产和销售。主营业务收入构成为：原料药及医药中间体56.07%，染料及染颜料中间体33.09% ...